Clinical trials: Human Papilloma Virus Infection
HPV Infection, Lesion Cervix
Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.
Observational clinical study, national, multicentric, prospective, non-comparative, with medical device, under application consistent with CE marking, for the evaluation of Papilocare® effectivness in the normalization of cervix…
- Trial name
- PAPILOBS (NCT04199260)
- Testing
- papilocare vaginal gel
- Where
- 9 sites in Spain
- Volunteers
- 263 people
- Sponsor
- Procare Health Iberia S.L.
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human…
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma
- Trial name
- NCT03439085
- Testing
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Human Papilloma Virus (HPV)
Human Papilloma Virus Awareness Intervention
Intervention aimed at increasing knowledge of the human papillomavirus in homosexual men as a means of preventing sexually transmitted diseases and controlling complications associated with the pathology.
- Trial name
- NCT06920589
- Testing
- Safe and Protected Sex" intervention targeting HPV, Diptych of the Secretary of Health in Mexico
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Univeristario Benemerita Universidad Autonoma de Puebla
Cervical Dysplasia
The Mother-Daughter Project: Merck-4
This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya.
- Trial name
- Merck-4 (NCT07240220)
- Testing
- Gardisil-9, High Risk HPV DNA Testing, Visual Inspection with acetic acid (VIA) and possible cervical biopsy
- Where
- Kenya
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Indiana University
Human Papilloma Virus, Hiv
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose…
- Trial name
- HOPE II (NCT06436274)
- Testing
- GARDASIL®9, Menveo®/Menactra®
- Where
- 3 sites in Botswana, Rwanda and 1 more
- Volunteers
- 778 people
- Sponsor
- Massachusetts General Hospital
Warts
Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.
The primary objective is to determine whether intralesional cidofovir is effective at bringing about the total or near-total resolution of warts that have already proven recalcitrant to standard therapy.
- Trial name
- NCT02567149
- Testing
- Cidofovir
- Where
- United States
- Sponsor
- University of Minnesota
Oropharynx Cancer, Pain
Functional Outcome After Treatment for Oropharyngeal Squamous Cell Carcinoma
To investigate the treatment related effects of transoral robotic surgery (TORS) or oncological treatment of oropharyngeal squamous cell carcinoma with a 1-year follow up.
- Conditions
- Oropharynx Cancer, Pain, Swallowing Disorder, Quality of Life
- Trial name
- NCT03418909
- Testing
- Primary Trans Oral Robotic Surgery (TORS), Radio(chemo)therapy
- Where
- Denmark
- Volunteers
- 44 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HPV, Vaccine Acceptance
Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention
This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.
- Conditions
- HPV, Vaccine Acceptance, Vaccine Decision Making, HPV Vaccination
- Trial name
- HPV-END-IT (NCT07632963)
- Testing
- HPV-Kompassen
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
HPV Vaccination, Uptake Vaccination
PREVENT Pilot HPV - Related Cancers Trial
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West.
- Conditions
- HPV Vaccination, Uptake Vaccination, Series Completion
- Trial name
- NCT06738355
- Testing
- PREVENT
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Utah
HPV Infection, Systemic Disease
Vaginal Self-sampling for Detecting High-risk Human Papillomavirus Cervical Infection in Patients With Immune-mediated Inflammatory Diseases
Main objective: -To determine Human Papilloma Virus (HPV) prevalence in patients with immune-mediated inflammatory diseases (IMID) using vaginal self-sampling (VSS), one year after VSS was proposed Primary endpoint: - To…
- Trial name
- APOSY (NCT06302725)
- Testing
- Vaginal self sampling detecting HPV
- Where
- France
- Volunteers
- 278 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HSIL of Cervix, HSIL, High Grade Squamous Intraepithelial Lesions
Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.
This study evaluates the use of ABI-1968, a topical cream, in the treatment of cervical precancerous lesions in females without human immunodeficiency virus (HIV) infection.
- Conditions
- HSIL of Cervix, HSIL, High Grade Squamous Intraepithelial Lesions, High-Grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus
- Trial name
- NCT03697226
- Testing
- Topical ABI-1968
- Where
- South Africa
- Volunteers
- 8 people
- Sponsor
- Antiva Biosciences
Oropharynx Squamous Cell Carcinoma
Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)
The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for…
- Trial name
- MER-HPV (NCT05649865)
- Testing
- Blood sample
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Region Skane
Human Papilloma Virus, Anal Squamous Cell Carcinoma
High Resolution Anuscopy Study
The majority of anal squamous cell carcinomas (SCC) stem from infection with high-risk human papillomavirus (HPV). Anal SCC is rare among the general population but affects several populations disproportionately.
- Trial name
- NCT06697964
- Testing
- HRA
- Where
- Belgium
- Volunteers
- 500 people
- Sponsor
- Universitair Ziekenhuis Brussel
Human Papillomavirus Infection, HPV
Human Papillomavirus in Young People Epidemiological Research 4
Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV.
- Conditions
- Human Papillomavirus Infection, HPV, HPV Infection, Anal Cancer
- Trial name
- HYPER4 (NCT05587738)
- Where
- Australia
- Volunteers
- 500 people
- Sponsor
- Monash University
Papillomavirus Infections
A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)
This study will evaluate whether co-administration of the first dose of V503 and REPEVAX™ is well tolerated and causes a non-inferior immune response when compared to administration of REPEVAX™ one month following the first dose…
- Trial name
- NCT01073293
- Testing
- V503 Vaccine, REPEVAX™ (Concomitant), REPEVAX™ (Non-concomitant)
- Volunteers
- 1,054 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
Background: Human papilloma virus (HPV) is a common sexually transmitted disease. There are more than 100 different HPV types, and both males and females can get HPV infection.
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
- Trial name
- NCT00798265
- Testing
- Gardasil, Survey
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Genital Human Papilloma Virus Infection
A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study
In this pilot study, we intend to demonstrate that a great portion of women at high risk (inadequate screening, HPV 16/18 and/or cytology) are presenting to the ED, cytology/ HPV testing via ThinPrep®Pap testTM and surveillance.
- Trial name
- NCT01133509
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Eastern Virginia Medical School
Papillomavirus Infections
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa.
- Trial name
- NCT01245764
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Warts
ERAP1,2 in Recalcitrant Warts
The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies.
- Trial name
- NCT06833164
- Testing
- endoplasmic reticulum Aminopeptidase 1 and 2, endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Benha University
Cervical Carcinoma, Human Papillomavirus Infection
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention.
- Trial name
- NCT06611553
- Testing
- Biospecimen Collection, Cervical Biopsy, Colposcopy
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.